Oncoptpeptides - Bring hope through science

Bringing hope through science

FDA approval of PEPAXTO - Webcast

In conjunction with the FDA approval of PEPAXTO, Oncopeptides hosted a webcast Monday March 1, 2021, including presentations by CEO Marty J Duvall, CSO Jakob Lindberg, CMO Klaas Bakker, and CFO Anders Martin-Löf. The webcast was recorded. 

More information

Oncopeptides vision

Vision of Oncopeptides

“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

CEO Marty J Duvall interviewed in Di.TV

CEO Marty J Duvall interviewed by Di.TV

In conjunction with the FDA approval, Oncopeptides' CEO Marty J Duvall was interviewed by the Swedish economy TV channel Di.TV Börsmorgon. See the interview (after about 30 sek the interview turns into English). 

See the interview

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions. 
Read more

Webcast - Cowen 41st Annual Health Care Conference

Oncopeptides presents at Cowen 41st Annual Health Care Conference March 3, 2021, at 17:00 (CET).

Read more

Released

Year-end report 2020

”A year of transformation”

CEO Marty J Duvall

 

See the Webcast


For further information, please contact:

Linda Holmström
Director of Investor Relations

Profile image

Press release -

FDA approves Oncopeptides' PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma

Read press release
Events Oncopeptides

Upcoming events

View calendar

Webinar Embassy of Sweden

Seminar at the Embassy of Sweden Washington DC

The Embassy of Sweden in Washington DC, Oncopeptides AB, Dana Farber and Uppsala University hosted a virtual seminar on February 2nd,“A Swedish American Journey of Cancer Research”. 

Read more

Cultures & Values

We are science and data driven, innovative and curious, making decisions based on systematic and thorough analyses.

Read more